CFH and retinal disorder: We present a case of Purtscher-like retinopathy secondary to aHUS due to complement factor H (CFH) mutation and resulting complement overactivation, successfully treated with systemic intravenous administration of eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, CT, USA), an inhibitor of terminal complement activation.